Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Metastatic × Interleukin-2 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 22 Neoplasm Metastasis 8 Carcinoma, Renal Cell 7 Ovarian Neoplasms 6 Lymphoma, Non-Hodgkin 6 Leukemia, Myeloid, Acute 6 Carcinoma, Non-Small-Cell Lung 6 Colorectal Neoplasms 5 Breast Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Stomach Neoplasms 4 Neuroblastoma 4 Neoplasms 4 Lymphoma 4 Prostatic Neoplasms 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Esophageal Neoplasms 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lung Neoplasms 2 Leukemia 2 Kidney Neoplasms 2 Glioblastoma 2

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡